Related Experiment Video
Updated: Apr 16, 2026
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
Machine learning-based multi-omic analysis identifies CEP55, DLGAP5, and EZH2 as regulated cell death biomarkers
Dinara Azanbayeva1, Awais Ali2, Omneya Abdelkarem3
1Department of dermatovenereology and Dermatocosmetology- NJSC, Astana Medical University, Astana, Kazakhstan.
Abstract:
Hepatocellular carcinoma (HCC) often exhibits limited responsiveness to immune checkpoint inhibitors (ICIs), largely due to an immunosuppressive tumor microenvironment (TME). Regulated cell death (RCD) pathways, including ferroptosis, necroptosis, and pyroptosis, possess immunogenic properties that may influence tumor-immune interactions and therapeutic responses. However, the prognostic significance of RCD-related genes and their relationship with immune suppression and anti-PD-1 resistance remain insufficiently understood. Two bulk RNA-seq datasets (GSE181947 and GSE248516) representing immunologically distinct HCC subtypes were analyzed to identify differentially expressed genes (DEGs). These were intersected with curated ferroptosis-, necroptosis-, and pyroptosis-related gene sets, yielding 36 differentially expressed RCD-related genes (DE-RCDRGs). Functional enrichment, protein-protein interaction (STRING and CytoHubba), and survival analyses (Kaplan-Meier Plotter, TCGA-LIHC) were performed to prioritize hub genes. Clinical correlations and epigenetic regulation were assessed using UALCAN. Expression validation was conducted across 24 liver cancer cell lines using Human Protein Atlas (HPA) RNA-seq data. Additionally, deleterious non-synonymous SNPs (nsSNPs) in prioritized genes were structurally characterized using integrative in silico modeling. Ten hub genes were identified, with CEP55, DLGAP5, and EZH2 emerging as key prognostic markers. These genes were significantly overexpressed in tumors, associated with advanced stage and poor differentiation, and showed aberrant DNA methylation. Functional enrichment linked them to oxidative stress response, mitotic regulation, and epigenetic control. Cell-line analysis showed CEP55 and DLGAP5 enrichment in SNU-series models, while EZH2 was highly expressed in HuH-6, Hep3B, and Huh7. Structural analysis further identified deleterious nsSNPs affecting critical functional domains. CEP55, DLGAP5, and EZH2 are identified as RCD-associated biomarkers linked to immune suppression and immunotherapy resistance in HCC.
Insights
Regulated cell death (RCD) genes impact hepatocellular carcinoma (HCC) immunotherapy response. CEP55, DLGAP5, and EZH2 are key prognostic markers linked to immune suppression and anti-PD-1 resistance in HCC.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) shows poor response to immune checkpoint inhibitors (ICIs) due to immunosuppressive tumor microenvironments.
- Regulated cell death (RCD) pathways (ferroptosis, necroptosis, pyroptosis) have immunogenic potential but their prognostic role in HCC and relation to ICI resistance is unclear.
Purpose of the Study:
- To investigate the prognostic significance of RCD-related genes in HCC.
- To explore the association between RCD-related genes, immune suppression, and resistance to anti-PD-1 therapy in HCC.
Main Methods:
- Analysis of two bulk RNA-seq datasets (GSE181947, GSE248516) to identify differentially expressed RCD-related genes (DE-RCDRGs).
- Functional enrichment, protein-protein interaction, survival analyses, clinical correlation, and epigenetic analysis were performed.
- Expression validation in HCC cell lines and in silico structural characterization of deleterious nsSNPs.
Main Results:
- Ten hub genes were identified, with CEP55, DLGAP5, and EZH2 highlighted as key prognostic markers.
- These genes were overexpressed in HCC, correlated with advanced stage, poor differentiation, and aberrant DNA methylation.
- Functional enrichment implicated these genes in oxidative stress, mitotic regulation, and epigenetic control, with specific expression patterns in HCC cell lines.
Conclusions:
- CEP55, DLGAP5, and EZH2 are identified as novel RCD-associated biomarkers in HCC.
- These biomarkers are linked to immune suppression and immunotherapy resistance, suggesting potential therapeutic targets.
